The human genome contains three relaxin genes, among which relaxin-2 (RLN2) shares similar antifibrosis effects with mouse relaxin-1 (RLN1) in murine fibrosis models, allowing early-stage development of human relaxin-based drugs to be tested in mouse models.21 Here, RLN1 is linked to fibrosis.